Oxford Vaccine Group launches world’s first Phase I Bundibugyo ebolavirus vaccine trial

Oxford Vaccine Group initiates the first Phase I trial for Bundibugyo ebolavirus vaccine with support from India's Serum ...

Oxford’s new Ebola vaccine enters first human trial: Serum Institute making over 6,20,000 doses

The CEPI-backed vaccine against the Bundibugyo strain of Ebola has reached Phase 1 trials just 57 days after the outbreak was declared.
The Financial Express

Serum stockpiles Ebola vaccine candidate; supplies does for Phase 1 trial

The Serum Institute of India rapidly produced 620,000 doses of the ChAdOx1 Bundibugyo ebolavirus vaccine and supplied 4,000 ...

Oxford Ebola Vaccine: What to Know About the New Shot Entering Human Trials

Oxford has launched the first human trial of a vaccine targeting the Bundibugyo strain of Ebola, as the death toll in the ...

Oxford begins first human trial of Bundibugyo Ebola vaccine

The Serum Institute of India has supplied 4,000 investigational doses for the Phase I study.

Moderna and other groups get $60 million to develop Ebola vaccine

Global health organisation CEPI will give roughly $60 million to Moderna and two other groups to accelerate the development of shots ​against Ebola Bundibugyo, the deadly virus that has swept through ...

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports ...

The Ugandan city where the race for a new Ebola vaccine will be won or lost

The small Ugandan city of Masaka is known mostly for its coffee, grown on rich volcanic soils that produce beans which have a ...